Periop. Cases on Endocrine Disorders Thomas Maniatis Dec. 16, 2010
Transcript
Slide 1
Periop. Cases on Endocrine Disorders Thomas Maniatis Dec. 16,
2010
Slide 2
Conflicts of Interest None
Slide 3
Case 65 female DM2 on glyburide 10 bid, pioglitazone 30 qd,
metformin 1g bid Cataract OR Cholecystecomy Colectomy for colon
CA
Slide 4
Issues to consider Patient Factors Type of diabetes Treatments:
Diet, oral agents, insulin Adequacy of control: loose, optimal,
tight Surgical Factors Minor, major Timing NPO starting when and
lasting how long
Slide 5
Preop control and periop complications No high-quality data
suggesting preop control impacts on periop complications Small
study suggested that HbA1c >7% associated with increased wound
infections Case-control study showed increased risk for wound
infections if sugars > 11 (CABG)
Slide 6
Effects of surgery on glucose control Stress response causing
increased glucose levels glucagon, epi, GH, IL-6 and TNF-alpha
Slide 7
Goals of therapy Prevent ketoacidosis Avoid marked hyper / hypo
glycemias Balanced fluids/electrolytes Tight vs. loose control
Varying evidence for tight control Improved outcomes in certain
populations at cost of increased hypos In general, loose control is
acceptable
Slide 8
Case 65 female DM2 on metformin 1 g bid, N 10-0-0-10 Cataract
OR Cholecystectomy Colectomy for CA Radical Neck Dissection for
neck mass
Slide 9
Case 55 male DM1 on rapid 12-14-18-0, glargine 0-0-0-20
Cataract OR Neck Biopsy under GA (day surgery) Cholecystectomy CABG
for CAD
Slide 10
IV Insulin How to write a protocol preop in stable patients
When to transition from IV to SC postop How to transition from IV
to SC postop
Slide 11
IV Insulin Protocols vary Separate insulin/dextrose vs.
combined GIK Targets: tight vs. traditional See Protocol
Calculation of starting dose Baseline total daily dose/24 safety
margin of 30- 50% Dextrose depends on fluid sensitivity D5 vs. D10
Monitoring, NPO, adjustments Start early to stabilize dose by
OR
Slide 12
Slide 13
IV insulin Intraop Managed by anaesthesia Postop Continue drips
until no longer NPO Plan transition to SC ahead of time
Slide 14
IVSC insulin transition post-op Look at baseline dose pre-op
Compare with current needs and take into account stressors
(infection, etc.) and PO intake Hourly dose x 24 = total daily
needs if control stable and eating well (and no infection)
Preferred transition to 3 injections of short- acting with meals
and 1 intermediate-long acting before bed while in hospital
Slide 15
IVSC insulin transition post-op Sliding scale Traditional vs.
adaptive sliding scale Monitor transition closely Modify baseline
doses daily Closer to discharge, collapse regimen down to
patient-appropriate protocol
Slide 16
Slide 17
Case 35 male Pituitary surgery for tumour Panhypopit.
subsequently Cort. 25/12.5, thyroxin, testosterone Hernia repair
Cholecystecomy Colectomy for mass
Slide 18
Case 65 female PMR on pred. 15/d Cataract Inguinal Hernia
Esophageal resection for tumour
Slide 19
Case 50 male Mod-severe COPD on intermittent prednisone 4 x per
year, inhaled steroids Exczema on topical steroids Cholecystectomy
Pneumonectomy for tumour
Slide 20
Effects of surgery on steroid secretion Basal secretion 8-10
mg/d of cortisol Minor surgery 50 mg/d Major surgery 75-100 mg/d
(up to 200 mg/d in severe stress) Timing Biggest surge is
immediately post-op (reversal of anaesthesia, extubation)
Slide 21
Surgery and steroids Assess reason for steroid exposure Primary
adrenal or pituitary disease vs. other Assess magnitude of exposure
Dose and duration Consider further testing of axis ACTH stimulation
using the 250 microg dose Uncertain meaning Need adequate time
Assess surgical stress
Slide 22
Effects of steroids on adrenal axis Likely not suppressed
Chronic use of < 5 mg of prednisone Any patient on any dose of
steroid for < 3 weeks Likely suppressed Any patient on > 20
mg of prednisone for > 3 weeks Any patient with clinical
Cushings Intermediate Everyone else!!
Slide 23
Surgery and steroids Supplement limited to immediate periop
period Hydrocortisone 50-100 mg IV pre-induction of anaesthesia,
then 25-50 mg IV Q8h x 3 doses, then halve dose QD to baseline dose
(or d/c) Be aware of risks of steroids periop Infections Impaired
wound healing
Slide 24
Thyroid disorders and surgery Poor evidence base supporting
recommendations Hypothyroidism associated with intraop. hypotension
in retrospective studies Mild-mod: may choose to postpone elective
surgery to optimize Severe: only emergency surgery, give T4 and T3
urgently Risk for myxedema coma Hyperthyroidism Beta blockers to
control HR Thionamides Risk for thyroid storm
Slide 25
Pheochromocytoma and surgery Medical preparation focuses on
avoiding hypertensive crises Alpha blockade starting 7-10 days
preop phenoxybenzamine Followed by beta blockade 2-3 days preop
Alternatives: Ca-channel blockers, metyrosine